Oslo, Norway, May 8, 2023 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced it will report its
financial results for the first quarter of 2023 on Friday, May 12, 2023, before
market open and subsequently host a webcast presentation at 10 a.m. CET.
A live and archived webcast of the presentation can be accessed in the Investors
section of the Company's website:
https://nykode.com/investors/financial-reports-and-presentations.
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies for the treatment of
cancer and infectious diseases. Nykode's modular vaccine technology specifically
targets antigens to Antigen Presenting Cells, which have been shown to induce
broad, strong and long-lasting antigen specific immune responses which
correlates with clinical responses.
Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive safety and efficacy results from its Phase 2 trial for the
treatment of cervical cancer